Alzheimers and Dementia Pharmaceutical Business News Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease By Staff Reports 7 months ago Pharma leaders, Biogen and Eisai, Co., Ltd. decided today to discontinue the global Phase 3
Pharmaceutical Business News ProNeurogen’s New Drug Candidate Shows Promise For Treating Cognitive Impairment By Staff Reports 8 months ago Cognitive impairment affects more than 50 million people worldwide. In the United States alone, one
Biotechnology Pharmaceutical Business News Lilly to buy Loxo Oncology in $8 billion cancer push By Staff Reports 9 months ago (Reuters) Eli Lilly and Co (LLY.N) said on Monday it would buy Loxo Oncology Inc
Biotechnology Pharmaceutical Business News Q BioMed Announces Strategic Partnership and Preclinical Development of Treatment for Pediatric Nonverbal Disorder in Autistic Children By Staff Reports 10 months ago Collaboration with SRI Provides QBioMed Expertise in Formulation Development and Preclinical Work in Autism, as
Pharmaceutical Business News FDA approves new treatment for rare hereditary disease By Staff Reports 1 year ago The U.S. Food and Drug Administration recently approved Takhzyro (lanadelumab), the first monoclonal antibody approved
Pharmaceutical Business News Cannabidiol-based Therapy Effective in Irritable Bowel Disease and Colitis: Early Study By Staff Reports 1 year ago FSD Pharma Inc. reports today that its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”), has
Pharmaceutical Business News Biogen, Eisai’s Alzheimer’s drug succeeds in mid-stage trial, shares soar By Staff Reports 1 year ago (REUTERS) Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a
Pharmaceutical Business News Set Back for Pancreatic Cancer: CARRIE study did not meet primary or secondary endpoints By Staff Reports 1 year ago Merrimack Pharmaceuticals, Inc., a clinical-stage oncology company focused on biomarker-defined cancers, today announced top-line results
Pharmaceutical Business News Shire bid marks Takeda’s latest – and biggest – push for global status By Staff Reports 1 year ago (Reuters) Takeda Pharmaceutical Co Ltd’s $64 billion bid for London-listed rare disease specialist Shire Plc
Pharmaceutical Business News Merck’s Keytruda helps lung cancer patients live longer in trial By Staff Reports 2 years ago Merck & Co’s blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in
Pharmaceutical Business News Celgene Partners with Prothena Therapeutics in Potential $2B Deal By Staff Reports 2 years ago (BioSpace) Shares of Prothena Corporation plc have shot up more than 18 percent in premarket
Pharmaceutical Business News FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing By Staff Reports 2 years ago The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients
Pharmaceutical Business News Merck KGaA and Pfizer’s Avelumab fails in trial By Staff Reports 2 years ago (Marketwatch) Merck KGaA and Pfizer Inc. said on Thursday that avelumab, a cancer immunotherapy, failed
Gene Therapy Pharmaceutical Business News Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy in Epidermolysis Bullosa By Staff Reports 2 years ago Gene therapy developer, Abeona Therapeutics, announced that the FDA has granted Regenerative Medicine Advanced Therapy
Pharmaceutical Business News Celgene to buy Juno for $9 billion to boost CAR-T expertise By Staff Reports 2 years ago (Reuters) – Celgene Corp announced a $9 billion cash buyout of Juno Therapeutics Inc on Monday as
Pharmaceutical Business News Merek’s KEYTRUDA Improved Overall Survival in Patients with Non-small Cell Lung Cancer By Staff Reports 2 years ago Merck announced that the pivotal Phase 3 KEYNOTE-189 trial investigating KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in
Pharmaceutical Business News Gilead to buy Kite Pharma in $11.9 billion deal By Staff Reports 2 years ago Reuters — Gilead Sciences agreed to buy Kite Pharma in a $11.9 billion deal on
Neurology Pharmaceutical Business News Data Showing Anti-Addictive/Pain Relief Benefits of Cannabinoids to be Presented at Upcoming Society of Neuroscience Meeting By Staff Reports 2 years ago Data recently obtained from Nemus Bioscience‘s research and development partner, the University of Mississippi (UM)
Pharmaceutical Business News Forge Therapeutics Raises $15M Series A Financing to Develop First Novel Gram-Negative Antibiotic in Decades By Staff Reports 2 years ago Forge Therapeutics, Inc., a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform,
Pharmaceutical Business News Sangamo Therapeutics and Pfizer Announce Collaboration for Hemophilia A Gene Therapy By Staff Reports 2 years ago Sangamo Therapeutics, Inc. and Pfizer Inc. announced this week, an exclusive, global collaboration and license